Poolbeg Pharma PLC (POLB)

London

Currency in GBP

8.30

-0.10(-1.19%)

Closed·16:35:59

Fair Value

Unlock Value

Day's Range

8.30

8.55

52 wk Range

3.30

9.20

Poolbeg Pharma (POLB) Income Statement & Profits

Assess the Poolbeg Pharma income statement (earnings report) to see how the company performs across operating and non-operating activities, including revenue, expenses and net income. Review POLB diluted EPS and profitability over the last four annual or quarterly periods.

Investors who need greater depth or who want to customise how data is presented to fit their own investment styles are able to do so via their very own InvestingPro account.

Period Ending:

2021

31/12

2022

31/12

2023

31/12

2024

31/12

2025

31/12

Total Revenues

Total Revenues Growth

Cost Of Revenues

Gross Profit

Gross Profit Growth

Gross Profit Margin %

Other Operating Expenses, Total

3.11

4.99

4.69

6.57

6.33

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

-	+60.08%	-6.02%	+40.23%	-3.65%
0.55	2.2	1.68	1.38	1.53
2.71	3.06	3.38	5.26	4.89
-0.15	-0.28	-0.37	-0.07	-0.09

Operating Income

-3.11

-4.99

-4.69

-6.57

-6.33

Operating Income Growth

-60.08%

+6.02%

-40.23%

+3.65%

EBIT Margin %

Net Interest Expenses

0.21

0.53

0.43

0.25

Net Interest Expenses Growth

+155.5%

-19.85%

-40.89%

Interest Expense, Total

Interest And Investment Income

0.21

0.53

0.43

0.25

Other Non Operating Expenses, Total

EBT, Excl. Unusual Items

-3.11

-4.78

-4.15

-6.14

-6.08

Gain (Loss) On Sale Of Assets

-0.26

-0.01

Other Unusual Items, Total

-0.35

0.46

0.31

EBT, Incl. Unusual Items

-3.11

-4.78

-4.51

-5.94

-5.77

EBT, Incl. Unusual Items Growth

-53.37%

+5.69%

-31.94%

+2.86%

EBT, Incl. Unusual Items Margin

Income Tax Expense

-0.09

-0.57

-0.15

-0.08

Net Income to Company

-3.11

-4.69

-3.93

-5.79

-5.7

Minority Interest

Net Income

-3.11

-4.69

-3.93

-5.79

-5.7

Net Income Growth

-50.45%

+16.11%

-47.29%

+1.64%

Net Income Margin %

Preferred Dividend and Other Adjustments

Net Income to Common Excl. Extra Items

-3.11

-4.69

-3.93

-5.79

-5.7

Basic EPS - Continuing Operations

-0.01

Basic EPS - Continuing Operations Growth

+4.54%

+16.11%

-47.29%

+18.4%

Diluted EPS - Continuing Operations

-0.01

Diluted EPS - Continuing Operations Growth

+4.72%

+15.96%

-46.84%

+18.54%

Basic Weighted Average Shares Outstanding

317.23

500

602.65

Diluted Weighted Average Shares Outstanding

317.23

500

602.65

Dividend Per Share

Dividend Per Share Growth

EBITDA

-3.09

-4.96

-4.66

-6.46

-6.27

EBITDA Growth

-60.48%

+6.05%

-38.56%

+2.87%

EBITDA Margin %

EBIT

-3.11

-4.99

-4.69

-6.57

-6.33

* In Millions of GBP (except for per share items)

FAQ

What was the quarter-over-quarter change in EBITDA for Poolbeg Pharma?

POLB's EBITDA changed by 0.00% compared to the last quarter.

FTSE 100

10,650.44

+41.52

+0.39%

DAX

25,557.16

+196.01

+0.77%

Euro Stoxx 50

6,322.25

+53.28

+0.85%

S&P 500

7,666.74

+74.95

+0.99%

Nikkei 225

64,011.34

-1,259.61

-1.93%

Dow Jones

52,597.26

+533.16

+1.02%

FTSE 100 Futures

10,674.80

+55.3

+0.52%

Market Movers

Name	Last	Chg. %	Vol.
Shell	3,551.0	+0.51%	6.92M
Rolls-Royce Holdings	1,454.60	+1.72%	14.20M
AstraZeneca	11,708.0	-0.43%	1.47M
BP	564.60	-0.09%	25.14M
HSBC	1,552.60	+1.54%	9.11M
British American Tobacco	4,100.0	+0.20%	3.44M
BAE Systems	1,898.00	-1.33%	6.97M

Name	Last	Chg. %	Vol.
Rapid Nutrition	2.8200	+100,000.00%	1.12K
Telecom Italia	7.616	+870.19%	687.06K
Energous Co	11.73	+606.63%	18.00
Trane Technologies	444.61	+404.26%	694.00
Marathon Petroleum	405.4700	+270.16%	2.47K
Inseego	4.45	+196.67%	151.00
Palatin Tech	11.84	+188.78%	1.00

Name	Last	Chg. %	Vol.
Booking	173.7	-96.45%	5.15K
Next Biometrics	0.25	-94.23%	267.00
MindMaze Therapeutics Holding	0.17	-93.95%	84.00
iQIYI	0.96	-92.44%	291.00
Kala Pharma	0.58	-91.57%	451.00
KLA Corp	181.89	-76.95%	4.57K
Inovio	1.25	-76.19%	43.89K

Trending Stocks

Name	Last	Chg. %	Vol.
Rolls-Royce Holdings	1,454.60	+1.72%	14.20M
Empyrean	0.073	+5.88%	935.83M
Glencore	605.50	+0.97%	18.89M
BP	564.60	-0.09%	25.14M
THG Holdings	26.26	-5.06%	30.99M

Most Undervalued Stocks

Name	Last	Upside	Fair Value
Aaaaaaaa	288.50	+37.46%	396.57
Aaa Aaa Aa	285.50	+33.36%	380.74
Aaaaaa Aa Aaaaa	2,490.00	+33.14%	3,315.19
Aaa Aaaa Aaa	1,770.50	+29.24%	2,288.19
Aaaaaaaaaaaaaa	564.60	+28.85%	727.49
Aaaaaaaaaaaaaaa Aa	1,603.0	+28.76%	2,064.0
Aaaaa Aaaa A Aaaa	707.20	+26.61%	895.39

Name	Last	Upside	Fair Value
Aaaaaaaa	288.50	+37.46%	396.57
Aaa Aaa Aa	285.50	+33.36%	380.74
Aaaaaa Aa Aaaaa	2,490.00	+33.14%	3,315.19
Aaa Aaaa Aaa	1,770.50	+29.24%	2,288.19
Aaaaaaaaaaaaaa	564.60	+28.85%	727.49
Aaaaaaaaaaaaaaa Aa	1,603.0	+28.76%	2,064.0
Aaaaa Aaaa A Aaaa	707.20	+26.61%	895.39

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Popular Searches

Please try another search

Poolbeg Pharma PLC (POLB)

Poolbeg Pharma (POLB) Income Statement & Profits

FAQ

What was the quarter-over-quarter change in EBITDA for Poolbeg Pharma?

Trending Stocks